163 related articles for article (PubMed ID: 35749236)
21. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling.
Li SW; Takahara T; Que W; Fujino M; Guo WZ; Hirano SI; Ye LP; Li XK
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G450-G463. PubMed ID: 33439102
[TBL] [Abstract][Full Text] [Related]
22. PRDX6 Promotes Fatty Acid Oxidation
Shen W; Yang L; Yang Y; Wang P; Tao X; Shen Y; Wang S; Shen Y
Antioxid Redox Signal; 2023 Jun; 38(16-18):1184-1200. PubMed ID: 36401357
[No Abstract] [Full Text] [Related]
23. Folic acid attenuates high-fat diet-induced steatohepatitis
Xin FZ; Zhao ZH; Zhang RN; Pan Q; Gong ZZ; Sun C; Fan JG
World J Gastroenterol; 2020 May; 26(18):2203-2220. PubMed ID: 32476787
[TBL] [Abstract][Full Text] [Related]
24. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
25. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
Ip E; Farrell G; Hall P; Robertson G; Leclercq I
Hepatology; 2004 May; 39(5):1286-96. PubMed ID: 15122757
[TBL] [Abstract][Full Text] [Related]
26. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
27. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
[TBL] [Abstract][Full Text] [Related]
28. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.
Chen T; Shi D; Chen J; Yang Y; Qiu M; Wang W; Qiu L
Mol Med Rep; 2015 Jan; 11(1):303-8. PubMed ID: 25333350
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
Yu DD; Van Citters G; Li H; Stoltz BM; Forman BM
Bioorg Med Chem; 2021 Jul; 41():116193. PubMed ID: 34022528
[TBL] [Abstract][Full Text] [Related]
33. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.
Velayudham A; Dolganiuc A; Ellis M; Petrasek J; Kodys K; Mandrekar P; Szabo G
Hepatology; 2009 Mar; 49(3):989-97. PubMed ID: 19115316
[TBL] [Abstract][Full Text] [Related]
34. Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia.
Jha P; Claudel T; Baghdasaryan A; Mueller M; Halilbasic E; Das SK; Lass A; Zimmermann R; Zechner R; Hoefler G; Trauner M
Hepatology; 2014 Mar; 59(3):858-69. PubMed ID: 24002947
[TBL] [Abstract][Full Text] [Related]
35. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
[TBL] [Abstract][Full Text] [Related]
36. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
Pawlak M; Lefebvre P; Staels B
J Hepatol; 2015 Mar; 62(3):720-33. PubMed ID: 25450203
[TBL] [Abstract][Full Text] [Related]
38. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target.
Smati S; Polizzi A; Fougerat A; Ellero-Simatos S; Blum Y; Lippi Y; Régnier M; Laroyenne A; Huillet M; Arif M; Zhang C; Lasserre F; Marrot A; Al Saati T; Wan J; Sommer C; Naylies C; Batut A; Lukowicz C; Fougeray T; Tramunt B; Dubot P; Smith L; Bertrand-Michel J; Hennuyer N; Pradere JP; Staels B; Burcelin R; Lenfant F; Arnal JF; Levade T; Gamet-Payrastre L; Lagarrigue S; Loiseau N; Lotersztajn S; Postic C; Wahli W; Bureau C; Guillaume M; Mardinoglu A; Montagner A; Gourdy P; Guillou H
Gut; 2022 Apr; 71(4):807-821. PubMed ID: 33903148
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
Régnier M; Polizzi A; Smati S; Lukowicz C; Fougerat A; Lippi Y; Fouché E; Lasserre F; Naylies C; Bétoulières C; Barquissau V; Mouisel E; Bertrand-Michel J; Batut A; Saati TA; Canlet C; Tremblay-Franco M; Ellero-Simatos S; Langin D; Postic C; Wahli W; Loiseau N; Guillou H; Montagner A
Sci Rep; 2020 Apr; 10(1):6489. PubMed ID: 32300166
[TBL] [Abstract][Full Text] [Related]
40. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
